Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130728 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 3
- Development phase
- 636
- Enrollment target
NCT00130728 is a Phase 3 study that has completed, run by Genentech. The registered enrollment target is 636 participants.
The verdict
NCT00130728, a Phase 3 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 636 participants
- Enrollment target
Study Summary
This is a Phase III, multicenter, placebo-controlled, double-blind, randomized study. Approximately 650 patients will be randomized in a 1:1 ratio to one of two treatment arms.
Interventions
- DRUG placebo
- DRUG bevacizumab
- DRUG erlotinib HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 636 participants |
| Start Date | 2005-06-08 |
| Est. Completion | 2019-12-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130728
The ClinicalTrials.gov registry entry for NCT00130728 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 636 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00130728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00130728 about?
NCT00130728 is a clinical study titled "A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer". This is a Phase III, multicenter, placebo-controlled, double-blind, randomized study. Approximately 650 patients will be randomized in a 1:1 ratio to one of two treatment arms.
What is the current status of trial NCT00130728?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 636 participants. The study started on 2005-06-08. Estimated completion is 2019-12-23.
What interventions are being tested in trial NCT00130728?
The interventions under investigation include: placebo (DRUG), bevacizumab (DRUG), erlotinib HCl (DRUG).
Who is sponsoring clinical trial NCT00130728?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.